Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Curcumin/gemcitabine

Next Previous
Drug Profile

Curcumin/gemcitabine

Alternative Names: Gemcitabine/curcumin; STO-2

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vascarta
  • Class Amines; Analgesics; Anti-ischaemics; Antianaemics; Antihistamines; Antineoplastics; Antivirals; Catechols; Chemopreventatives; Deoxyribonucleases; Fluorinated hydrocarbons; Ketones; Nonsteroidal anti-inflammatories; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antimetabolites; Antioxidants; CCR2 receptor antagonists; Chemokine CCL 5 inhibitors; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; DNA synthesis inhibitors; HIV integrase inhibitors; Immunosuppressants; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell stabilisers; Platelet aggregation inhibitors; Thromboxane synthase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 04 Jul 2025 Curcumin/gemcitabine is available for licensing as of 04 Jul 2025. https://vascarta.com/partnering/
  • 04 Jul 2025 Preclinical trials in Pancreatic cancer in USA (Parenteral) (Vascarta pipeline, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top